Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures
Tóm tắt
The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant to antibiotics, we studied its bactericidal kinetics, synergistic effect, resistance, and activity on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. The bactericidal rate of S-thanatin was more than 99% against K. pneumoniae ATCC 700603 when bacterial cultures were monitored for 60 min. The peptide was synergistic with β-lactam cefepime in most of the clinical MDR isolates tested (7/8). An average value of FIC was 0.3708. No synergy was found between the peptide and amoxicillin, gentamycin, tetracycline, or ciprofloxacin in all bacteria tested. A total of 48 isolates of K. pneumoniae with different resistance spectrum tested was susceptible to S-thanatin. The MICs were 6.25–25 μg/ml. No significant difference in the MICs of S-thanatin between the sensitive isolates and the resistant isolates to single antibiotic was observed (P > 0.05). The resistance of K. pneumoniae ATCC 700603 to S-thanatin was slightly higher, when cultured at sub-inhibitory concentration for 5 days. S-thanatin may be an attractive candidate for developing into an antimicrobial agent.
Tài liệu tham khảo
Rubinstein E, Zhanel GG (2007) Anti-infectives research and development problems, challenges and solutions: the clinical practitioner perspective. Lancet Infect Dis 7:69–70
Lockhart SR, Abramson MA, Beekman SE et al (2007) Antimicrobial resistance among gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45:3352–3359
Ylipalosaari P, Ala-Kokko TI, Laurila J et al (2006) Epidemiology of intensive care unit (ICU)-acquired infections in a 14 month prospective cohort study in a single mixed Scandinavian university hospital ICU. Acta Anaesthesiol Scand 50:1192–1197
Zhanel GG, DeCorby M, Laing N, The Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ et al (2008) Antimicrobial-resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005–2006. Antimicrob Agents Chemother 52:1430–1437
Moland ES, Hanson ND, Black JA et al (2006) Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 44:3318–3324
Mulvey MR, Bryce E, Boyd D et al (2004) The Canadian Hospital Epidemiology Committee of the Canadian Nosocomial Infection Surveillance Program, Health Canada. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella sp. in Canadian hospitals. Antimicrob Agents Chemother 48:1204–1214
Landman D, Bratu S, Kochar S et al (2007) Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 60(1):78–82
Fehlbaum P, Bulet P, Chemysh S et al (1996) Structure activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci USA 93:1221–1225
Wu GQ, Li LX, Ding JX et al (2008) High-level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli. Curr Microbiol 57:95–101
Hirsch T, Jacobsen F, Steinau HU et al (2008) Host defense peptides and the new line of defence against multiresistant infections. Protein Pept Lett 15:238–243
Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238–250
Giuliani A, Pirri G, Bozzi A et al (2008) Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell Mol Life Sci 65:2450–2460
Wu GQ, Ding JX, Li H et al (2008) Effects of cations and pH on antimicrobial activity of TS and S-thanatin against Escherichia coli ATCC25922 and B. subtilis ATCC 21332. Curr Microbiol 57:552–557
National Committee for Clinical Laboratory Standards (2001) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA
Khandelia H, Ipsen JH, Mouritsen OG (2008) The impact of peptides on lipid membranes. Biochim Biophys Acta 1778:1528–1536
Shai Y, Makovitzky A, Avrahami D (2006) Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections. Curr Protein Pept Sci 7:479–486
Ulvatne H, Vorland LH (2001) Bactericidal kinetics of β-lactoferricins against Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 33:507–511
Steinberg DA, Hurst MA, Fujii CA et al (1997) Protegrin-1: a broad spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother 41:1738–1742
Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551–1557